Hip Innovation Technology Leadership

Board of Directors

George Diamantoni, Chief Executive Officer, Manager and Chairman of the Board

George Diamantoni is currently the Chief Executive Officer, Manager and Chairman of the Board to Hip Innovation Technology, LLC. He is the Founder and Chief Executive Officer of Joint Innovation Technology, LLC, which is the holder of the majority of the Class A Membership Interests of the Company for which he provides executive leadership. Mr. Diamantoni has over 25 years of professional experience in the health care industry, including 20 years with The Upjohn Company, Pharmacia Corporation, Pfizer Inc., and Schering Plough Corporation, multinational pharmaceutical corporations, and 5 years with Allos Therapeutics, Inc., an oncology company; and Bone Care International, Inc., a specialty pharmaceutical company. Mr. Diamantoni has previously served as a consulting Partner for Direkt Finance, a privately held international investment firm. In this position, he established and led a health care-focused investment division. Mr. Diamantoni has held the offices of Vice President for Government Affairs, Strategic Alliances, Reimbursement and Managed Accounts, Customer Marketing, and Sales with his previous employers. He obtained his Bachelor of Arts in Biology and Chemistry from Kalamazoo College in Kalamazoo, Michigan.

James Caruso

James Caruso is a Senior Life Sciences Executive with a 27 year record of success with medical device start-up, mid-tier biotechnology, specialty and multinational pharmaceutical companies. He is currently the President and Chief Executive Officer of Cellectar Biosciences, Inc., an oncology company. Most recently, he served as our Executive Vice President and Chief Operating Officer. He was previously the Executive Vice President, Chief Commercial Officer of Allos Therapeutics, Inc., an oncology company acquired by Spectrum Pharmaceuticals. Mr. Caruso was Senior Vice President, Sales and Marketing, at Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation. Prior to that, Mr. Caruso was Vice President of Neuroscience Specialty Sales at Novartis, a pharmaceutical company. He served as Vice President, Sales, of BASF Pharmaceuticals-Knoll, a pharmaceutical company that was acquired by Abbott Corporation. For 12 years, Mr. Caruso held various commercial-focused positions, including senior management roles, at Bristol-Myers Squibb Company, a pharmaceutical company. Mr. Caruso earned a Bachelor of Science in Finance from the University of Nevada in 1988.

Chris Fashek

Chris Fashek is the CEO at Atteris Healthcare LLC. Prior to his current role, he was Chairman, President and CEO at Spiracur Inc., President & Executive Chairman Systagenix Wound Management, Ltd. and Vice Chairman of KCI. Mr. Fashek led KCI's Therapeutic Services division (KCTS) from 1995 to 1999, and he also led KCI USA business, which included Therapeutic Surfaces and the V.A.C. from 1999 to 2005, when he was appointed Vice Chairman of KCI USA. He is an accomplished healthcare executive with a winning record of leading billion dollar global medical-device and pharmaceutical businesses. Mr. Fashek has mastered the full-product lifecycle, taking multiple healthcare products from ideation to commercialization; as well as turning-around underperforming corporations to profitability. He is recognized globally as an achiever, strategic thinker and solid decision maker and has developed an influential network of industry partners resulting in new business opportunities and bottom-line growth. Mr. Fashek continues to be an Advisory Board member of the IDN Summit, a number of charitable boards, the World Craniofacial Foundation, and Our Lady of the Lake University. Mr. Fashek has a Bachelor's degree from Upsala College and an M.B.A. from Fairleigh Dickinson University.

Victor Frankel, M.D., Ph.D.

Dr. Frankel is an independent orthopaedic and biomechanical consultant to the medical device industry and has advised leading companies in the medical device sector. He currently is President Emeritus, Hospital for Joint Diseases Orthopaedic Institute and a Professor of Orthopaedic Surgery, New York University School of Medicine. Dr. Frankel presently serves on the Board of Directors of the Musculoskeletal Transplant Foundation (MTF), the nation’s largest tissue bank, which he co-founded. Most recently, Dr. Frankel served as President, Hospital for Joint Diseases Orthopaedic Institute. He has held numerous prestigious positions throughout his distinguished career, including Professor and Chairman, Department of Orthopaedics, University of Washington, and Professor of Orthopaedic Surgery, Case Western Reserve University. Prior Board of Director positions include the Hospital for Joint Diseases, American Society for Testing and Materials (ASTM), and the Orthopaedic Research & Education Foundation. He has performed educational lectures throughout the world and has authored 12 Orthopaedic biomechanics-focused textbooks, contributed an additional 40 chapters to medical texts, and published 115 articles. Dr. Frankel received a B.A. in Zoology from Swarthmore College, an M.D. from the University of Pennsylvania School of Medicine, and a Ph.D. in Biomechanics and Orthopaedic Surgery from the University of Uppsala, Sweden.

Kevin Sidow

Kevin Sidow is President and Chief Executive Officer of Moximed, Inc. Prior to his current role, he was President and CEO of St. Francis Medical Technologies, Inc. (SFMT). Founded in 1997, St. Francis Medical Technologies was a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies, Inc., was sold for $725 million to Kyphon Inc. Prior to joining SFMT, Mr. Sidow was the Worldwide President of DePuy Inc. As former Worldwide President of DePuy, his responsibilities included the combined worldwide reconstructive business (hips, knees, extremities, operating room products, ACE and casting), Spine, Mitek (sports medicine) and Biologics with annual revenue responsibility of over $3 billion. Mr. Sidow has over 20 years of orthopaedic medical device experience and holds a B.S. in Accounting from West Virginia University.

Zafer Termanini, M.D., F.A.C.S., President and Chief Medical Officer

Dr. Zafer Termanini is the company’s President and Chief Medical Officer. Dr. Termanini is a Fellow of the American College of Surgeons, and is certified by the American Board of Orthopaedic Surgery as an orthopaedic surgeon with over 30 years of experience. He is a member of the American Academy of Orthopaedic Surgeons. He is also a Diplomate of the American College of Disability Analysts and the American College of Forensic Examiners, with specialties in Orthopaedic and Joint Reconstruction, Sports Medicine and Biomechanical Analysis. Dr. Termanini, inventor of the Interlocking Reverse Hip, currently holds 8 U.S. patents and 6 U.S. patent applications. Five of his patents have been sold and successfully commercialized. He has served as Chief of Orthopaedic Surgery and General Surgery at East Orange General Hospital and has privileges in several New Jersey hospitals, including Newark Beth Israel Medical Center, Saint Barnabas Medical Center, and Meadowlands Hospital Medical Center. He is licensed in New Jersey, New York, and Georgia. Dr. Termanini received his C.P.E.M. degree, with honors, from the College Scientifique Universitaire in Angers, France, in 1967 and his medical degree, with honors, from the Université d’Angers in Angers, France, in 1973. He also attended the prestigious school of “Arts et Métiers” where he studied Biomechanical Engineering.